High-Dose Vitamin D Speeds Healing of Chemo and Radiation Skin Toxicities

Oncology nurses are often the first to identify the painful, red, and sometimes blistering skin reactions that can sideline a patient’s cancer treatment. These cutaneous toxicities — specifically toxic erythema of chemotherapy (TEC) and acute radiation dermatitis (ARD) — frequently necessitate treatment interruptions, compromising oncologic outcomes.

However, a new multicenter study published in JAMA Dermatology suggests that a simple, high-dose oral supplement might offer a rapid and safe solution for these debilitating side effects.

A Rapid Response for Skin Distress

The retrospective case series, which included 33 patients across three academic medical centers, evaluated the impact of high-dose oral vitamin D (hdVD) on patients experiencing severe skin toxicities. Participants received one or two doses of 100,000 international units (IU) of cholecalciferol or ergocalciferol.

The results were striking: 87% of patients reported subjective symptom relief within just 10 days of receiving the supplement. For oncology nurses managing patient comfort, the speed of this intervention is particularly noteworthy. The median time to improvement was 5 days overall, and even faster for the inpatient subgroup, who saw relief in a median of just 3 days.

Clinician-assessed objective improvement was also significant. Using a 5-point Likert scale to grade erythema (redness), researchers found that mean scores dropped from a baseline of 4.36 to 2.21 by day 10. This shift represents a transition from inflammatory erythema, often accompanied by bullae or desquamation, to muted or nonexistent redness.

Clinical Relevance for Nurses

For nursing staff, identifying which patients might benefit most is key. The study found that certain TEC subtypes responded most rapidly to hdVD, including neutrophilic eccrine hidradenitis (NEH) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)–like eruptions.

The study also highlighted the specific therapies most frequently associated with these skin reactions in the cohort, with liposomal doxorubicin being the most common culprit (27%), followed by enfortumab vedotin (12%) and cytarabine (9%). Nurses administering these agents should be particularly vigilant in monitoring for early signs of cutaneous distress.

Safety and Treatment Continuity

Perhaps the most critical finding for the broader oncology team is that hdVD facilitated the continuation of anticancer therapy in 73% of patients without interruption. In an environment where every missed dose can impact a patient's prognosis, the ability to manage toxicities while staying on schedule is invaluable.

Furthermore, the safety profile of hdVD was excellent. Despite the "high-dose" label, researchers observed no meaningful changes in serum calcium levels and no treatment-related adverse events. This aligns with previous data suggesting that single oral doses of vitamin D up to 600,000 IU can be administered safely even in critically ill populations.

Mechanism of Action

Vitamin D is more than just a bone health supplement; it acts as a potent immunomodulator. The study authors explain that hdVD may attenuate acute inflammation by suppressing pro-inflammatory signaling pathways (such as interleukin 17) and enhancing tissue repair through the polarization of M2 macrophages. Essentially, hdVD helps "dampen" the initial cutaneous injury caused by cytotoxic agents or radiation.

Key Takeaways for Oncology Nurses

• Rapid Relief: High-dose vitamin D (100,000 IU) is associated with symptom relief (pain and pruritus) in a median of 5 days.
• Treatment Continuity: Use of hdVD may prevent treatment interruptions, with nearly three-quarters of patients in the study continuing their primary cancer therapy.
• Safety Profile: No instances of hypercalcemia or vitamin D toxicity were reported, and serum calcium levels remained stable.
• Target Subtypes: Patients with NEH and SJS/TEN-like subtypes of TEC showed the most rapid responses.
• Addressing Deficiency: Many cancer patients are already vitamin D deficient; hdVD may address this underlying insufficiency while treating acute skin injury.

Action Items for Nursing Practice

• Screen and Assess: Routinely assess patients receiving high-risk agents (e.g., liposomal doxorubicin, cytarabine) for early signs of TEC using standardized skin assessment tools.
• Collaborate on Protocols: Discuss the integration of hdVD into supportive care protocols with the oncology and dermatology teams, especially for patients showing early signs of ARD or TEC.
• Monitor Labs: While the study showed high safety, continue to monitor standard calcium and renal function (eGFR) as part of routine oncology care.
• Patient Education: Educate patients that hdVD is being used for its "rapid immunomodulator" effects on the skin rather than standard nutritional supplementation.
• Document Response: Carefully document the time to symptom relief and changes in erythema following hdVD administration to help build institutional evidence for this supportive care approach.

While larger prospective controlled trials are needed to define optimal dosing and long-term efficacy, this study provides a promising, low-cost, and safe tool for the oncology nursing arsenal.

Reference

1. Patil MK, Sakunchotpanit G, Toulmin SA, et al. High-dose oral vitamin D for toxic effects of the skin associated with chemotherapy and radiation. JAMA Dermatol. Published online July 15, 2026. doi:10.1001/jamadermatol.2026.2267.